858 Therapeutics Announces FDA Fast Track Designation for PARG Inhibitor ETX-19477 for the Treatment of Patients with BRCA-Mutated, HR+/HER2- Unresectable or Metastatic Breast Cancer

— Fast Track designation granted by U.S. FDA for evaluation of ETX-19477 in patients with BRCA-mutated HR+/HER2- unresectable or metastatic breast cancer — — Enables access to expedited regulatory review processes, including potential eligibility for accelerated approval and priority review — — Ongoing Phase 2 monotherapy cohorts in BRCA-mutated ovarian and breast cancer — SAN […]